BCWM
VKTX icon

Ball & Co Wealth Management’s Viking Therapeutics VKTX Stock Holding History

Ball & Co Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3K Hold
100
– – ﹤0.01% 63
2026
Q1 		$3K Hold
100
– – ﹤0.01% 67
2025
Q4 		$3K Hold
100
– – ﹤0.01% 66
2025
Q3 		$2K Hold
100
– – ﹤0.01% 77
2025
Q2 		$2K Hold
100
– – ﹤0.01% 61
2025
Q1 		$2K Hold
100
– – ﹤0.01% 57
2024
Q4 		$4K Buy
+100
New +$5.7K ﹤0.01% 56

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Ball & Co Wealth Management's VKTX Position: Q2 2026 in Review

Ball & Co Wealth Management held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 100 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #63.

Ball & Co Wealth Management first reported a position in VKTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $4K in Q4 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Ball & Co Wealth Management held 100 shares of Viking Therapeutics worth $3K as of Q2 2026.
  • Ball & Co Wealth Management left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Ball & Co Wealth Management's portfolio in Q2 2026, its #63 holding.
  • Ball & Co Wealth Management first reported a position in Viking Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Ball & Co Wealth Management's Viking Therapeutics position peaked at $4K in Q4 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Ball & Co Wealth Management's 13F filing for Q2 2026, filed 31 Jul 2026.